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Abstract
Background: Non-invasive diagnostic strategies aimed at identifying biomarkers of lung cancer
are of great interest for early cancer detection. The aim of this study was to set up a new method
for identifying and quantifying volatile organic compounds (VOCs) in exhaled air of patients with
non-small cells lung cancer (NSCLC), by comparing the levels with those obtained from healthy
smokers and non-smokers, and patients with chronic obstructive pulmonary disease. The VOC
collection and analyses were repeated three weeks after the NSCLC patients underwent lung
surgery.
Methods: The subjects' breath was collected in a Teflon® bulb that traps the last portion of single
slow vital capacity. The 13 VOCs selected for this study were concentrated using a solid phase
microextraction technique and subsequently analysed by means of gas cromatography/mass
spectrometry.
Results: The levels of the selected VOCs ranged from 10-12 M for styrene to 10-9 M for isoprene.
None of VOCs alone discriminated the study groups, and so it was not possible to identify one
single chemical compound as a specific lung cancer biomarker. However, multinomial logistic
regression analysis showed that VOC profile can correctly classify about 80 % of cases. Only
isoprene and decane levels significantly decreased after surgery.
Conclusion: As the combination of the 13 VOCs allowed the correct classification of the cases
into groups, together with conventional diagnostic approaches, VOC analysis could be used as a
complementary test for the early diagnosis of lung cancer. Its possible use in the follow-up of
operated patients cannot be recommended on the basis of the results of our short-term nested
study.
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Background
Breath analysis seems to be a promising approach to iden-
tify new biomarkers of inflammatory and oxidative lung
processes, and different volatile organic compounds
(VOCs) of endogenous or exogenous origin have been
analyzed to study lung diseases [1] and characterize envi-
ronmental and occupational exposure to chemical pollut-
ants [2].
During the 1970s, Pauling et al.[3] determined more than
200 components in human breath, some of which have
subsequently been associated with different pathological
conditions on the basis of their effect and/or their meta-
bolic origin.
In 1985, Gordon et al. identified several alkanes and mon-
omethylated alkanes in the exhaled air of lung cancer
patients [4], an observation that aroused interest because
of the possible use of exhaled biomarkers for early detec-
tion of the disease. Classical screening procedures, such as
chest radiography and sputum cytology, have not
decreased the number of deaths due to lung cancer [5],
but promising results have recently been obtained using
novel imaging techniques such as low-dose helicoidal
computed tomography [6], although cost effectiveness
and possible over-diagnosis seem to be serious issues.
There is therefore a considerable need for non-invasive
diagnostic procedures aimed at identifying lung cancer at
an early stage and adding specificity to imaging
techniques.
In 1999, Phillips et al. [7] selected 22 VOCs – mainly
alkanes and benzene derivatives – to distinguish subjects
with and without lung cancer, and have recently modified
the VOC pattern subject to statistical analysis by reducing
them to nine [8]. Selected alkanes and methylated alkanes
have proved to be highly discriminating in distinguishing
lung cancer patients from healthy controls, but breath
analyses can be affected by both clinical and analytical
confounding variables [9]. The published studies have
included mixed groups of patients with primary small or
non-small cell lung cancer (NSCLC) and lung metastases,
and did not compare VOC levels in lung cancer patients
with those in asymptomatic smokers or subjects suffering
from chronic obstructive pulmonary disease (COPD),
both of which may precede or be associated with the
development of lung cancer and which may characterise
the people undergoing screening procedures [10,11]. Fur-
thermore, there are no data supporting the usefulness of
VOC analysis in the follow-up of patients after tumour
resection. Finally, only a qualitative approach has been
used to identify selected VOCs, without any attempt to
quantify the individual components. Actual breath con-
centrations could increase the statistical power of compar-
isons aimed at identifying differences between groups and
between repeated measurements in the same individuals.
The aim of this study was to set up a new method for iden-
tifying and quantifying selected VOCs in exhaled air, and
apply it to a cross-sectional study of NSCLC and COPD
patients, and healthy control smokers and non-smokers,
and a short-term follow-up study of patients undergoing
surgery for NSCLC.
Methods
Study design
The design of the present study included a cross-sectional
investigation during which 13 selected VOCs were meas-
ured in air exhaled by NSCLC and COPD patients, and
asymptomatic control smokers and non-smokers. A sub-
sequent nested short-term follow-up study of the NSCLC
patients was carried out with repeat VOC sampling and
analysis about three weeks (range 2 – 4) after they had
undergone tumor resection (T1).
Subjects
We enrolled 36 patients who underwent tumor resection
because of histological evidence of NSCLC at the Univer-
sity of Parma's Department of Thoracic Surgery. The
assessments of tumour size and nodes were based on the
International Union Against Cancer TNM staging system
[12], and all of the patients were classified as having stage
Ia, Ib and IIa lung cancer. None of the patients received
radiation or chemotherapy before surgery.
The study also included 25 subjects with clinically stable,
mild to moderate COPD, all of whom were diagnosed on
the basis of the GOLD guidelines [13]. In brief, the entry
criteria, consisted of a post-bronchodilator FEV1 of <80%
the predicted value, an FEV1/FVC ratio of <70%, β2-ago-
nist-reversibility at baseline FEV1 of <200 ml and/or 15%,
and the absence of clinical asthma or other significant res-
piratory diseases. None of them had experienced any
worsening in symptoms over the previous eight weeks.
The asymptomatic controls were 35 smokers and 50 non-
smokers. The smokers had to have normal spirometry val-
ues (FEV1  and FEV1/FVC) and not be suffering from
chronic bronchitis; the non-smokers had to have no pul-
monary symptoms or a history of pulmonary disease, and
normal lung spirometry results. The smokers did not
smoke for at least one hour before breath collection.
Twenty-six of the NSCLC patients agreed to repeat the
breath collection during a follow-up visit 15–30 days after
surgery; the other 10 were excluded from the nested fol-
low-up study because their clinical condition had signifi-
cantly worsened.Respiratory Research 2005, 6:71 http://respiratory-research.com/content/6/1/71
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Table 1 shows the characteristics of the study subjects, all
of whom gave their informed consent.
Breath collection
After carrying out a series of experiments in order to estab-
lish a reliable sampling procedure, we modified the
breath sampling procedure recommended by the manu-
facturer of a commercially available device (Bio-VOC®
sampler, Markes International Ltd, Rhondda Cynon Taff,
UK) (Figure 1). Briefly, after 60 minutes' rest, the subjects
were asked to perform a single slow vital capacity breath
into a one-way valve connected to a Teflon®-bulb, which
traps the last portion of exhaled air (150 ml).
Twenty environmental samples were taken from the
rooms in which the subjects performed the test in order to
compare breath and ambient air VOC levels.
VOC extraction and analysis
After breath collection, 1 µL of n-heptane-d16 and styrene-
d8 methanolic solution (1.5 × 10-5 M) was added to each
sample as internal standard (IS) for respectively aliphatic
and aromatic compounds. The exhaled VOCs and IS were
extracted by means of SPME using a 75 µm Carboxen/
PDMS fibre (Supelco, Bellefonte, PA, USA), which was put
into the Bio-VOC® breath sampler for 30 min at room
temperature and then thermally desorbed in GC injection
port at 280°C. The GC/MS analysis was carried out using
a Hewlett-Packard HP 6890 gas chromatograph coupled
with an HP 5973 mass selective detector (Palo Alto, CA,
USA). The VOCs were separated on an Equity™-1 column
(30 m, 0.25 mm i.d., 1.0 µm film, Supelco) and acquired
in full-scan mode in 40–350 m/z range.
Thirteen VOCs (seven aliphatic and six aromatic com-
pounds) were selected, each of which was identified by
means of its mass spectrum and confirmed by comparing
its retention time with that of pure standard and charac-
teristic fragment ions; only the substances that did not
interfere with co-eluting compounds were chosen.
The preliminary experiments addressed methodological
issues, defined standard operating procedures, and vali-
dated analytical methods of VOC collection and analysis.
The factors affect the SPME process, such as adsorption
and desorption times and sampling temperature, were
optimized. The extraction time profile at room tempera-
ture (22°C) was 30 min and not markedly different
among the compounds. The SPME fibre was immediately
transferred to the GC-injector port in order to avoid the
loss of the extracted substances and avoid analyte evapo-
ration [14]. No carry-over effects were observed when des-
orption was performed at 280°C for 5 min.
The method was validated by studying the linear range,
and the limits of detection and precision. Linearity was
established over four orders of magnitude (1012-10-8 M,
r2>0.98) and the limits of detection, calculated as a signal/
noise ratio of about 3, was about 10-12 M for all the com-
pounds. Analytical precision, calculated as % RSD, was
within 3.1–13.7% for all of the intra- and inter-day deter-
minations on standards. The gaseous standards were
directly prepared in the Bio-VOC® bulb filled with helium,
1 µL of VOC methanolic standard solution, 1 µL of IS (1.5
× 10-5 M), and 6 µL of deionised water. The standards were
stabilised at room temperature for almost one hour and
remained stable up to 60 hours.
Statistical analysis
As the benzene and toluene levels had a log-normal distri-
bution (the Kolmogorov-Smirnov normality test) para-
metric tests were used for the cross-sectional study (one-
way ANOVA followed by the Games Howell post-hoc
test). Non-parametric statistics (Kruskal-Wallis test fol-
lowed by Dunn's Post Hoc test) were used for the other
VOCs, whose distribution was not normal even after log-
Table 1: Demographic characteristics of studied groups.
NSCLC COPD Controls Smokers
Subjects (n°) 36 25 50 35
Age (median, years) 67.2 70.2 55.7 54.1
Sex (male/female) 28/8 18/7 27/23 30/5
Current smokers 2 1 0 35
Ex smokers 28 21 0 0
Ever smokers 6 3 50 0
*Pack-years 20 20 n.a. 25 ± 2.6
FEV1 (% predicted) 69.8 ± 15.2 61.7 ± 13.4 105.6 ± 9.1 101.8 ± 10.2
The ex-smokers subjects had stopped smoking for at least one year. * Pack-years (mean ± SD) among current smokers. NSCLC = non-small cell 
lung cancer; COPD = chronic obstructive pulmonary disease; n.a. = not applicable.Respiratory Research 2005, 6:71 http://respiratory-research.com/content/6/1/71
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transformation. The cases were classified by means of
multinomial logistic regression using group codes as the
dependent variable and all of the VOC concentrations
(except total xylenes because of their high correlation with
ethylbenzene: r>0.95) as predictors. Interpretable factors
based on VOC levels were obtained by means of principal
component analysis (Varimax rotation with Kaiser's nor-
malization) [15]. The Keiser Meyer Olkin (KMO) test was
used to test sample adequacy (considered acceptable if the
KMO constant was >0.60), and the number of factors was
chosen on the basis of the flex point of the graph of
decreasing eigenvalues; the percentage of variance
explained was also recorded.
In the case of the follow-up study, Student's t  test for
repeated measures was applied to the benzene and tolu-
ene levels; Wilcoxon's test was used for all of the other
VOCs.
A p value of <0.05 was considered significant for all of the
statistical analyses. SPSS 13.0 (SPSS inc. Chicago, IL, USA)
and PRISM 3.0 (Graphpad, San Diego, CA) were used for
the statistical analyses.
Results
Tables 2 and 3 respectively summarise the VOC levels and
the statistical significances of the between-group differ-
ences. As all of the VOCs showed significant differences
between at least two group pairs, the overall p values of
the Kruskal-Wallis and ANOVA tests for individual VOCs
fell between 7.5 × 10-13 (for Ethylbenzene) to 1.6 × 10-3
(isoprene). For these highly significant differences, adjust-
ments for multiple testing calculated using Holm's test
(less conservative than Bonferroni's test [16]) did not
affect the results. The levels of 10 of the 13 substances
were significantly higher in the NSCLC patients than in
control non-smokers; the levels of 9 were higher in the
COPD patients and control smokers than in control non-
smokers.
The NSCLC patients had significantly higher 2-methyl-
pentane and isoprene levels and significantly lower
Breath collection and VOC extraction Figure 1
Breath collection and VOC extraction. The subjects performed a single slow vital capacity into a Teflon® bulb (Bio-VOC® 
breath sampler) (a) which traps the last portion of exhaled air (150 mL); the VOCs were extracted by directly inserting a 75 
mm Carboxen/PDMS SPME fiber (30 min) into the bulb (b).Respiratory Research 2005, 6:71 http://respiratory-research.com/content/6/1/71
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ethylbenzene and styrene levels than the COPD patients,
and significantly lower benzene, heptane and toluene lev-
els than the control smokers. In comparison with the con-
trol smokers, the COPD patients had lower 2-
methylpentane, benzene and toluene levels, and higher
styrene levels.
Exhaled breath of non-smoking controls had higher levels
of isoprene and heptane than the environmental air,
whereas NSCLC and COPD patients and control smokers
showed higher levels of almost all substances (data not
shown).
Principal component analysis (table 4), with a KMO con-
stant of 0.83, distinguished three factors with eigenvalues
>1, of which the third was the flex point of the graph of
decreasing eigenvalues. The first grouped benzene, hep-
tane, toluene, ethylbenzene, trimethylbenzene with an
explained variance of 27.5% (total xylenes were excluded
because of their high correlation with ethylbenzene:
r>0.95); the second grouped octane, styrene, pentameth-
ylheptane and decane with an explained variance of 20%,
and the third grouped pentane, isoprene and methylpen-
tane with an explained variance of 19%. The total
explained variance of the model was therefore 66.5%.
In order to test the discriminant power of the exhaled
VOC pattern, a multinomial logistic regression was made
using the coding group as the output variable and the con-
centration of all of the VOCs except total xylenes as pre-
Table 2: Exhaled VOC levels in studied groups
Controls (10-12 M) NSCLC (10-12 M) COPD (10-12 M) Smokers (10-12 M)
Isoprene 3789 (1399 – 6589) 6041 (3130 – 8863) 1758 (453 – 4981) 7243 (1361 – 16968)
2-Methylpentane 27.7 (3.4 – 50.3) 139.5 (65.7 – 298.8) 44.7 (21.7 – 63.8) 109.8 (62.8 – 173.5)
Pentane 268.0 (107.7 – 462.7) 647.5 (361.3 – 1112.5) 477.7 (261.5 – 1547.4) 511.4 (241.3 – 1128.3)
Ethylbenzene 13.6 (10.8 – 15.1) 24.0 (13.6 – 32.6) 51.1 (26.9 – 132.7) 39.7 (21.7 – 74.1)
Xylenes total 31.1 (21.1 – 56.4) 68.9 (43.6 – 108.4) 94.8 (49.7 – 131.9) 85.8 (60.1 – 185.2)
Trimethylbenzene 6.2 (4.7 – 11.0) 14.9 (9.3 – 22.1) 18.5 (10.4 – 25.4) 18.9 (11.9 – 44.9)
Toluene 80.8 (58.9 – 140.0) 158.8 (118.7 – 237.5) 158.5 (103.5 – 269.7) 453.5 (169.6 – 745.7)
Benzene 44.7 (27.7 – 68.6) 94.5 (62.2 – 132.2) 73.3 (51.8 – 95.4) 269.2 (84.6 – 745.1)
Heptane 8.4 (5.0 – 15.3) 13.5 (1.5 – 34.0) 47.3 (13.9 – 98.0) 98.0 (40.3 – 161.7)
Decane 208.7 (14.3 – 405.5) 568.0 (277.9 – 1321.6) 737.3 (524.6 – 1177.6) 239.2 (60.0 – 884.0)
Styrene 12.3 (5.3 – 21.8) 17.9 (8.5 – 37.2) 87.6 (56.0 – 148.8) 7.2 (2.8 – 41.6)
Octane 20.2 (4.0 – 50.8) 61.0 (22.4 – 112.9) 52.5 (31.9 – 147.2) 33.5 (19.7 – 57.8)
Pentamethylheptane 0.9 (0.1 – 2.6) 2.5 (1.2 – 9.7) 2.0 (1.2 – 7.6) 5.8 (1.2 – 16.5)
Concentrations expressed as median values(25th -75th percentile).
Table 3: Statistical differences between groups.
NSCLC vs. 
Controls
COPD vs. 
Controls
Smokers vs. 
Controls
NSCLC vs. 
COPD
NSCLC vs. 
Smokers
COPD vs. 
Smokers
Isoprene n.s. n.s. n.s. p < 0.05 n.s. P < 0.01
2-Methylpentane p < 0.001 p < 0.05 p < 0.001 p < 0.001 n.s. P < 0.05
Pentane p < 0.001 p < 0.05 p < 0.05 n.s. n.s. n.s.
Ethylbenzene p < 0.01 p < 0.001 p < 0.001 p < 0.05 n.s. n.s.
Xylenes total p < 0.001 p < 0.001 p < 0.001 n.s. n.s. n.s.
Trimethylbenzene p < 0.01 p < 0.001 p < 0.001 n.s. n.s. n.s.
Toluene p  <  0 . 0 0 1n . s . p  <  0 . 0 0 1n . s . p  <  0 . 0 0 1P  <  0 . 0 1
Benzene p  <  0 . 0 0 1n . s . p  <  0 . 0 0 1n . s . p  <  0 . 0 0 1P  <  0 . 0 5
Heptane n.s. p < 0.01 p < 0.001 n.s. p < 0.001 n.s.
Decane p < 0.001 p < 0.01 n.s. n.s. n.s. n.s.
Styrene n.s. p < 0.001 n.s. p < 0.001 n.s. P < 0.001
Octane p < 0.001 p < 0.01 n.s. n.s. n.s. n.s.
Pentamethylhepta
ne
p < 0.001 n.s. p < 0.001 n.s. n.s. n.s.
The significance of the multiple comparisons inside the individual univariate tests. ANOVA followed by Games Howell Post Hoc test for benzene 
and toluene, Kruskal-Wallis test followed by Dunn's Post Hoc test for all the other VOCs were performed.Respiratory Research 2005, 6:71 http://respiratory-research.com/content/6/1/71
Page 6 of 10
(page number not for citation purposes)
dictors: concentrations were used because they are direct
measures with an intrinsic experimental error and there-
fore more appropriate than the ratio between exhaled
breath and air VOC concentration, a function derived
from two different experimental measures by means of
mathematical manipulations. Figure 2 shows the correct
classification of cases into four groups as the Cox and
Snell pseudo R-square of the model was 0.83 (goodness-
of-fit test). In general, 82.5% of subjects were correctly
classified: a maximum of 87.8% for control non-smokers
and a minimum of 72.2% for the NSCLC patients. Analy-
sis of residuals did not reveal any particular cases with an
undue influence on the model or the overall classifica-
tion. On the basis of these results, the overall sensitivity
(calculated as NSCLC true positive/ true positive + false
negative) was 72.2% and overall specificity (calculated as
NSCLC true negative/ true negative + false positive) was
93.6%.
In the follow-up study of the NSCLC patients, only iso-
prene and decane significantly decreased after surgery (p <
0.05, table 5).
Discussion
Non-invasive diagnostic strategies aimed at identifying
biomarkers of early lung cancer probably require the use
of a panel rather than single substances [17]. The main
finding of our study was that none of selected VOCs alone
distinguished the NSCLC patients from the other study
groups (i.e. non of them was a specific biomarker of
NSCLC), but overall VOC concentrations were highly dis-
criminant (>70%). Owing to the limited sensitivity and
specificity of VOC analysis, a NSCLC diagnosis only based
only VOC concentrations in exhaled breath cannot be rec-
ommended at this stage. We did not calculate positive and
negative predictive values, as they are highly dependent
on the prevalence of the condition being examined in the
population at hands. Owing to the low prevalence of
NSCLC even in selected groups at high risk, the positive
predicted value of exhaled VOCs is expected to be low,
and should probably be used to rule out, rather than to
confirm NSCLC in subjects with suspect nodules.
Moreover, exhaled breath analysis is a particularly inter-
esting strategy but is still hampered by the lack of a stand-
ardised breath collection system and putative exhaled
biomarkers.
Our simple method of breath collection has a number of
advantages: i) it samples a fixed volume of air and dis-
cards anatomic dead space air; ii)  its fixed resistance
allows a reasonably constant expiratory flow; iii) it has no
carry-over effects and permits the addition of internal
standards to the breath samples, which improves data
reproducibility; and iv) it is a well-tolerated, suitable for
screening purpose, and also applicable to difficult clinical
and psychological conditions such as those observed in
NSCLC patients.
Further studies are needed to evaluate the VOC levels
obtained from repeated expirations or tidal breathing, but
the collection procedures require respiratory devices
equipped with instruments that control ventilatory pat-
tern [18], and this may limit their widespread application.
We selected 13 VOCs from the chromatographic profile of
exhaled breath on the basis of the detectability of the peak
and their biological significance, ten of which have been
previously used for discriminant lung cancer analysis by
Phillips et al. [7]; the other three were markers of oxidative
stress such as pentane with its methylated form (2-meth-
ylpentane), and toluene, which is closely related to ciga-
rette smoke.
The fact that we identified fewer VOCs than Phillips et al.
[7] may have been partially due to differences in our
breath sampling procedures: rather than concentrating
the breath sample in a sorbent trap [19], we collected
breath VOCs from a single expiration and extracted them
using SPME fibre. The SPME technique may be less sensi-
tive, but has the advantages of not requiring sample prep-
aration or any specific equipment for GC analysis [20];
furthermore, it allowed us to measure most of the sub-
stances of interest proposed in the literature. Another rea-
son for the difference in VOC identification may be the
different clinical characteristics of lung cancer patients: we
enrolled early-stage NSCLC patients because they may
benefit more from early detection strategies.
Table 4: Principal Components analysis of variables.
Factors
Group 1 2 3
Isoprene 10 . 7 9 7
2-Methylpentane 10 . 5 6 2
Pentane 10 . 5 3 1
Ethylbenzene 20 . 8 5 1
Trimethylbenzene 20 . 7 9 4
Toluene 20 . 7 7 3
Benzene 20 . 7 2 8
Heptane 20 . 6 2 9
Decane 30 . 8 7 8
Styrene 30 . 7 0 4
Octane 30 . 6 4 3
Pentamethylheptane 30 . 5 9 2Respiratory Research 2005, 6:71 http://respiratory-research.com/content/6/1/71
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There were no significant differences between the level of
most of the VOCs in the exhaled air of the control non-
smokers and those in the ambient air, which suggests that
ambient levels may influence the VOCs exhaled by
healthy non-smokers (data not shown). However, the
VOC levels in diseased patients were not explainable
solely by ambient VOC concentrations during breath col-
lection, because the samples of all of the study subjects
were collected in the same place. The NSCLC and COPD
patients and the control smokers had generally higher lev-
els of all of the exhaled VOCs than the control non-smok-
ers (except for isoprene in the COPD group), which
reflects differences in exhaled air composition due to
pathological conditions or smoking rather than environ-
mental contamination.
Various approaches have been adopted in an attempt to
distinguish endogenous substances from exogenous con-
taminants, such as correcting exhaled VOC concentrations
by subtracting inspiratory VOC levels or by calculating
alveolar gradients [7]. However, although these methods
are easy to perform, they do not take into account the
complexity of pulmonary adsorption and exhalation of
volatile substances [2].
Although the exact origin of exhaled VOCs remains to be
demonstrated, principal components analysis (PCA) fac-
torised the compounds into three groups (table 4) and
suggests some fascinating hypoteses. It may be particu-
larly relevant in distinguishing substances of endogenous
Classification of cases with multinomial logistic regression analysis Figure 2
Classification of cases with multinomial logistic regression analysis. ** Correctly classified cases. 82.5% of the sub-
jects were correctly classified.Respiratory Research 2005, 6:71 http://respiratory-research.com/content/6/1/71
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origin from those influenced by confounding factors
mainly related to tobacco smoke.
Isoprene, pentane and 2-methylpentane are grouped
together (group 1, factor 3). These substances can be con-
sidered mainly endogenous compounds even though
pentane and its methylated forms are also present in vehi-
cle engine exhausts [21] and isoprene is also a constituent
of tobacco smoke [22]. In humans, isoprene is formed
from acetilCoA and is the basic molecule in cholesterol
biosynthesis [23], and pentane comes from human lipid
peroxidation [24]. The grouping of these with 2-methyl-
pentane is in line with the results of a previous study that
considered methylated alkanes as a secondary product of
human oxidative stress [25], although the exact source of
methylated alkanes is still debated [26].
Of the group 1 substances, 2-methylpentane levels were
higher in NSCLC patients than in the control non-smok-
ers and COPD patients, which suggests its potential use-
fulness in screening procedures (probably in combination
with other relevant biomarkers). In line with previous
observations [27], pentane levels were higher in the
exhaled air of the patients with NCSLC and COPD and
asymptomatic smokers than in the control non-smokers,
but did not differentiate the first three groups from each
other.
Also in line with previously published studies [27,28],
isoprene levels were significantly higher in the breath than
in the environmental samples (data not shown), and
higher in the NSCLC patients and control smokers than in
the COPD patients. The between-group differences are
difficult to interpret, but are probably related to the mod-
erate effect of cigarette smoke on isoprene levels, and par-
tially to the lung destruction (emphysema) often affecting
COPD patients. In this regard, although no studies have
compared breath isoprene levels in NSCLC and COPD
patients, lower levels have been observed in the exhaled
breath of patients with acute respiratory distress syn-
drome (ARDS) in comparison with those without ARDS
[29].
The substances belonging to group 2 (factor 1) could be
classified mainly as smoking-related exogenous com-
pounds because their levels were higher in the control
smokers than control non-smokers. Ethylbenzene may be
of particular interest because of its ability to distinguish
NSCLC and COPD patients, and control non-smokers.
The substances belonging to group 3 (factor 2) are heter-
ogeneous and it is therefore more difficult to interpret the
between-group differences in the levels of the individual
substances.
The results of the VOC analysis of our nested short-term
follow-up study of surgically treated NSCLC patients
showed that only isoprene and decane levels significantly
decreased after surgery (Table 5), thus indicating that
breath VOC analysis cannot be recommended as a short-
term follow-up procedure in such patients.
Conclusion
Although none of the individual exhaled VOC alone was
specific for lung cancer, a combination of 13 VOCs does
allow the classification of cases into groups. Exhaled VOC
analysis may therefore be useful in improving the specifi-
city and sensitivity of conventional diagnostic approaches
to lung cancer. However, these findings will require vali-
dation in larger clinical studies.
Table 5: VOCs levels at T0 (before surgery) and T1 (after surgery).
T0 T1
Isoprene 6121 (4069–9031) *4125 (2415–7407)
2-Methylpentane 139.5 (68.8–291.6) 123.5 (81.1–227.6)
Pentane 647.5 (388.5–1013) 529.5 (329.6–960.0)
Ethylbenzene 24.0 (14.8–28.0) 19.7 (15.7–34.5)
Xylenes total 69.0 (45.8–105.6) 67.8 (51.2–129.4)
Trimethylbenzene 15.2 (10.1–22.3) 13.2 (10.2–22.5)
Toluene 161.9 (118.7–232.5) 160.3 (119.0–232.7)
Benzene 95.7 (62.9–132.2) 99.6 (60.0–119.2)
Heptane 15.1 (0.9–34.6) 18.7 (9.5–39.5)
Decane 625.0 (322.6–1392) *443.0 (197.0–920.7)
Styrene 22.1 (11.5–38.1) 18.0 (12.1–43.1)
Octane 65.7 (45.8–131.4) 49.7 (28.5–102.5)
Pentamethylheptane 2.6 (1.7–10.0) 2.5 (1.1–8.8)
* means a statistically significant difference (p < 0.05). The data are expressed as median (25th -75th percentile).Respiratory Research 2005, 6:71 http://respiratory-research.com/content/6/1/71
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List of abbreviation used
COPD = Chronic Obstructive Pulmonary Disease; GC/MS
= Gas Chromatography/Mass Spectrometry; IS = internal
standard; NSCLC = Non-Small Cells Lung Cancer; PCA =
Principal Components Analysis; SPME = Solid Phase
Microextraction; VOC = Volatile Organic Compound; tri-
methylbenzene = 1,2,4- trimethylbenzene; pentamethyl-
heptane = 2,2,4,6,6-pentamethylheptane.
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